Genmab — November 2017

bibob

Enig Mcjean.

JKY_VH

Ser heller ingen langsigtet grund til at hænge med klarinetten.

MrEbbe

Er der nogen der ved vedr. udviklingen af tisotumab vedotin mod og dara mod solide tumorer, bliver de også afprøvet i en kombi af de to midler?

Bulder

Det gør de ikke. Winkel sagde på q&a: We believe that a combination between daratumumab and ADCs is supported by
preclinical data but it is too premature to comment on that specific combination.

Bulder

Det er jo nok fordi de lige vil se hvordan dara ter sig i solide.

MrEbbe

Okay tak Bulder!

E_L

wouldn't that be interesting Bulder, if they would both work, they have 1 with JNJ and 1 with Seattle Genetics. For the 1st no costs, but for the 2nd more input and split revenues

E_L

but to
o far away to be dreaming about already

bibob

Yes E L. But keep dreaming. No tax on dreams.

E_L

MrEbbe

That would be very interesting indeed!

MrEbbe

But when is it that we can expect readouts on the trial with dara in solid tumors?

Helge_LarsenPI-redaktør

PBH..Derfor er Genmab faldet 15% de seneste tre måneder: https://play.borsen.dk/social/5a08a59f45628ff817212e99

E_L

Janssen Korea’s ‘paradigm-changing’ blood cancer drug gets approval http://www.koreabiomed.com/news/articleView.html?idxno=1878

E_L

and if you speak chinese; Darzalex entered the Top100 sales worldwide for the first 9months of the year http://www.chinapharm.com.cn/News/Detail.aspx?ID=39600 or via google translate https://translate.google.nl/translate?hl=nl&sl=zh-CN&tl=en&u=http%3A%2F%2Fwww.chinapharm.com.cn%2FNews%2FDetail.aspx%3FID%3D39600

JKY_VH

Tak for tippet Helge.

JørgenVarnæs

Ham Per Hansen skal man vist ikke tage alt for seriøst - 15% fald over 3 måneder på basis af JJ's Q3 rapportering...

Mcjean

er det ikke nærmere 20%

JørgenVarnæs

I øvrigt, så må udlandet udsalg af GEN aktier over den seneste måned have været ret markant, hvis man tager BlackRocks ~2% point forøgelse i betragtning

JørgenVarnæs

mon ikke snarere der var tale om 20% på en måned?